{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Monitoring-Visit-Reports-and-Communication-Timelines”
},
“headline”: “SOP for Monitoring Visit Reports and Communication Timelines”,
“description”: “This SOP defines procedures for preparing, reviewing, and communicating monitoring visit reports in clinical trials, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP standards while maintaining inspection readiness.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 23/12/2025
Standard Operating Procedure for Monitoring Visit Reports and Communication Timelines
| Department | Clinical Operations / Monitoring |
| SOP No. | CR/OPS/067/2025 |
| Supersedes | NA |
| Page No. | 1 of 32 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to define standardized procedures for preparing, reviewing, approving, and communicating monitoring visit reports (MVRs) in clinical trials. This
Scope
This SOP applies to CRAs/monitors, sponsors, CROs, clinical operations staff, principal investigators, and QA officers involved in monitoring activities. It covers preparation of MVRs, communication timelines for sharing reports and follow-up letters, CAPA documentation, and archiving of monitoring-related correspondence.
Responsibilities
- CRA/Monitor: Prepares draft monitoring visit reports, discusses findings with PI, and submits reports on time.
- PI: Reviews findings, implements corrective actions, and ensures site-level compliance.
- Clinical Operations Manager: Reviews MVRs for completeness and ensures timely sponsor communication.
- Sponsor/CRO: Oversees adherence to report timelines and ensures findings are addressed appropriately.
- QA Officer: Audits MVRs and communication processes to verify compliance with SOP and regulatory standards.
Accountability
The sponsor is accountable for ensuring MVRs are prepared, reviewed, and filed within defined timelines. CRAs are accountable for accuracy and completeness of reports. Clinical operations managers are accountable for communication of findings and follow-up.
Procedure
1. Preparation of Monitoring Visit Report (MVR)
CRA prepares draft MVR within 5 working days of monitoring visit.
Include sections on informed consent, source data verification, IP accountability, protocol compliance, deviations, and site staff training.
Use standardized templates approved by sponsor (Annexure-1).
2. Internal Review and Approval
Clinical Operations Manager reviews MVR within 3 working days of submission.
Sponsor reviews and approves within 7 working days.
Approved report filed in TMF and ISF.
3. Communication to Sites
Share approved MVR with PI and site within 10 working days of visit.
CRA prepares follow-up letter summarizing major findings and CAPA requirements (Annexure-2).
PI acknowledges receipt and provides CAPA response within 15 working days.
4. CAPA Documentation
Record all CAPAs in CAPA Log (Annexure-3).
CRA tracks CAPA implementation until closure.
Sponsor verifies closure prior to next monitoring visit.
5. Escalation
Critical findings (fraud, serious safety concerns) must be escalated to sponsor within 24 hours.
Document in Escalation Log (Annexure-4).
6. Timelines
Draft MVR: within 5 working days.
Sponsor review/approval: within 7 working days.
Site communication: within 10 working days.
CAPA response: within 15 working days.
7. Archiving
Archive MVRs, follow-up letters, CAPA logs, and escalation records in TMF/ISF.
Retain for at least 15 years or as per local regulations.
Abbreviations
- SOP: Standard Operating Procedure
- PI: Principal Investigator
- CRA: Clinical Research Associate
- CRO: Clinical Research Organization
- QA: Quality Assurance
- TMF: Trial Master File
- ISF: Investigator Site File
- MVR: Monitoring Visit Report
- CAPA: Corrective and Preventive Action
Documents
- Monitoring Visit Report Template (Annexure-1)
- Follow-Up Letter Template (Annexure-2)
- CAPA Log (Annexure-3)
- Escalation Log (Annexure-4)
References
- ICH E6(R2) – Good Clinical Practice
- FDA – Guidance on Risk-Based Monitoring
- EMA – Clinical Monitoring Guidelines
- CDSCO – Monitoring Report Requirements
- WHO – Monitoring Visit Recommendations
Version: 1.0
Approval Section
| Prepared By | Ravi Kumar, CRA |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Principal Investigator |
Annexures
Annexure-1: Monitoring Visit Report Template
| Section | Details |
|---|---|
| Visit Date | [dd/mm/yyyy] |
| Site | [Site ID/Name] |
| Key Findings | [Summary] |
| Deviations | [Number/Details] |
Annexure-2: Follow-Up Letter Template
| Date | Site | Summary of Findings | CAPA Required |
|---|---|---|---|
| [dd/mm/yyyy] | [Site Name] | [Summary] | [Action Required] |
Annexure-3: CAPA Log
| Date | Issue | CAPA | Responsible | Status |
|---|---|---|---|---|
| 15/09/2025 | Incomplete drug accountability | Training + reconciliation | PI | Open |
| 17/09/2025 | Delayed CRF entries | Retraining provided | CRA | Closed |
Annexure-4: Escalation Log
| Date | Issue | Escalated To | Resolution | Closed By |
|---|---|---|---|---|
| 18/09/2025 | Critical GCP violation | Sponsor | Investigation initiated | QA Officer |
| 19/09/2025 | Serious safety concern | Regulator | Site suspended | Sponsor |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head, Clinical Operations |
For more SOPs visit: Pharma SOP